Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
However, it is important to consult a healthcare professional prior to intravenous glutathione therapy
Titrate: Step up to ~4,000 mcg (~15 units) around weeks 36 as tolerated
PMID: 130 SzabadkaiG.BianchiK.VarnaiP.De StefaniD.WieckowskiM
S.AhmadI.AlraeyY.SiddiquiS.et al (2024)
They really listen to your needs and set up a regimen that works for you." WRC Patient, 2.5 months Important Note on Scale Weight vs
Special Population Considerations Population pharmacokinetic analyses revealed: Body weight influences GLP2 exposure (approximately 1.1% change per kg) Renal impairment (including end-stage renal disease) does not significantly impact pharmacokinetics Hepatic impairment (mild to severe) does not require dose adjustments Age, sex, race, and ethnicity do not have clinically relevant effects on GLP2 pharmacokinetics Study Populations GLP2 clinical research has included the following participant groups: Adults with type 2 diabetes Primary focus of SURPASS trials (over 6,000 participants) Adults with obesity or overweight SURMOUNT trials for chronic weight management Participants with metabolic comorbidities Including metabolic syndrome, prediabetes Heart failure patients with HFpEF and obesity SUMMIT trial population Adults with obstructive sleep apnea and obesity SURMOUNT-OSA studies Various demographic populations Multinational studies across diverse racial and ethnic groups Research Limitations & Regulatory Status Critical Gaps in Current Evidence Despite an extensive clinical development program, important limitations remain in the GLP2 evidence base
